AI	aromatase inhibitor
CBR	clinical benefit rate
CI	confidence intervals
DPN	2,3-bis(4-hydroxy-phenyl)-propionitrile
EAOC	endometriosis associated ovarian cancer
ER	estrogen receptor
ERα	estrogen receptor alpha
ERβ	estrogen receptor beta
EOC	epithelial ovarian cancer
GCT	granulosa cell tumors
GPER1	G protein-coupled estrogen receptor 1
HGSOC	high grade serous ovarian cancer
HRT	hormone replacement therapy
IGFBP	insulin-like growth factor-binding protein
LGSOC	low grade serous ovarian cancer
MPP	1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride
mutESR1	mutated estrogen receptor alpha
PHTPP	4-[2-phenyl-5,7-bis(trifluoromethyl) pyrazolo [1,5-a]-pyrimidin-3-yl]phenol
PPT	4,4′,4″-(4-propyl-[1H]-pyrazole-1,3,5-triyl) trisphenol
RR	relative risk